Verastem Oncology

About Verastem Oncology

Verastem Oncology is dedicated to developing innovative treatments for patients with RAS pathway-driven cancers, which are often aggressive and recurrent. The company aims to provide better options and hope for patients by pursuing novel RAS-targeted treatment combinations, ensuring no cancer patient runs out of options.

Products & Services

Avutometinib (RAF/MEK Clamp):A first-in-class RAF/MEK clamp that blocks RAF and MEK signaling in the RAS pathway, preventing reactivation of tumor growth pathways. It is in late-stage clinical development and has potential as a backbone therapy for various RAS pathway-driven cancer treatments.

Defactinib (FAK Inhibitor):A FAK inhibitor that works in combination with Avutometinib to block compensatory FAK activation, providing a more complete blockade of tumor growth signaling in RAS pathway-driven cancers.

Specialties

RAS Pathway-Driven Cancer Treatments RAF/MEK Inhibition FAK Inhibition Novel Cancer Therapy Combinations

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 90000000 MR: - FA: approximately $90 million FAN: 90000000	D: 2025-11-14 FD: 2025-11-14	4 investors
2	RT: Private Placement T: - FT: Private Placement	A: 75000000 MR: - FA: 75 million FAN: 75000000	D: 2025-04-25 FD: 2025-04-25	6 investors
3	RT: Public Offering T: - FT: Public Offering	A: 55000000 MR: - FA: 55.0 million FAN: 55000000	D: 2024-07-23 FD: 2024-07-23	2 investors
4	RT: Public Offering T: - FT: Public Offering	A: 85000000 MR: - FA: 85.0 million FAN: 85000000	D: 2023-06-16 FD: 2023-06-16	5 investors
5	RT: Private Placement of Series B Convertible Preferred Stock T: - FT: Private Placement of Series B Convertible Preferred Stock	A: 60000000 MR: - FA: up to $60 million FAN: 60000000	D: 2023-01-24 FD: 2023-01-24	1 investors

Public Offering Latest

2025-11-14

$90.0M

4 investors (Pro only)

Private Placement 2025-04-25

$75.0M

Public Offering 2024-07-23

$55.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Dan Paterson

President and Chief Executive Officer

D

Dan Calkins

Chief Financial Officer

C

Cathy Carew

Chief Organizational Effectiveness Officer

M

Mike Crowther

Chief Commercial and Strategy Officer

J

John Hayslip

Chief Medical Officer

J

Jonathan Pachter

Chief Scientific Officer

View 19 more team members with Pro

Unlock Full Team Directory

Recent News